Enterprise Value

2.341B

Cash

6.536B

Avg Qtr Burn

-191.3M

Short % of Float

10.99%

Insider Ownership

22.49%

Institutional Own.

72.68%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

sNDA

Submission

Brepocitinib Details
Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis

Phase 3

Data readout

Batoclimab Details
Eye disease , Thyroid Eye Disease

Phase 3

Data readout

Batoclimab Details
Myasthenia gravis

Phase 3

Data readout

RVT-3101 Details
Ulcerative colitis

Phase 3

Initiation

RVT-3101 Details
Crohns disease

Phase 2

Data readout

Phase 2

Data readout

RVT-2001 Details
Myelodysplastic syndrome

Failed

Discontinued